Your session is about to expire
← Back to Search
PET Imaging for Bladder Cancer (PET MUSE Trial)
N/A
Waitlist Available
Led By Som Mukherjee, MD
Research Sponsored by Ontario Clinical Oncology Group (OCOG)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Men and women with newly diagnosed muscle-invasive high grade urothelial carcinoma of the bladder (TNM stage T2a-T4a, N0-3, M0), who are eligible for either radical cystectomy or radiotherapy-based bladder conservation
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights
PET MUSE Trial Summary
This trial will test whether PET-CT can improve the accuracy of staging for bladder cancer, which could lead to better treatment and outcomes.
Who is the study for?
This trial is for adults with newly diagnosed muscle-invasive bladder cancer, who can undergo surgery or radiation. They should be aiming for curative treatment and able to lie still for imaging tests. It's not suitable for those under 18, very ill (ECOG >2), pregnant, breastfeeding, have poor liver function, had major pelvic surgery or another invasive cancer in the last 5 years.Check my eligibility
What is being tested?
The study is testing if a whole-body PET-CT scan using FDG (a radioactive glucose compound) can better stage bladder cancer compared to standard CT scans. This could lead to more tailored treatments like extended lymph node removal or pre-surgery chemotherapy.See study design
What are the potential side effects?
While the document doesn't list specific side effects of FDG PET-CT, common ones include discomfort from lying still during the scan and potential allergic reactions to the FDG tracer. There's also exposure to low levels of radiation.
PET MUSE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have a new diagnosis of a serious bladder cancer and am eligible for major surgery or radiation.
PET MUSE Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Treatment received
Secondary outcome measures
Disease-free survival
Health economic analysis
Overall survival
+1 moreOther outcome measures
Change in planned management
Clinical and pathology response to chemotherapy using interim response of FDG PET-CT after 2 cycles of chemotherapy
PET MUSE Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Whole-body FDG PET-CTExperimental Treatment1 Intervention
Whole-body FDG PET-CT (Experimental arm)
Group II: No PET-CTActive Control1 Intervention
No PET-CT (Control arm)
Find a Location
Who is running the clinical trial?
Ontario Clinical Oncology Group (OCOG)Lead Sponsor
62 Previous Clinical Trials
41,593 Total Patients Enrolled
Cancer Care OntarioOTHER
16 Previous Clinical Trials
91,741 Total Patients Enrolled
Som Mukherjee, MDPrincipal InvestigatorJuravinski Cancer Centre
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have had part of my bladder surgically removed.You should not have FDG PET-CT due to health reasons.I have not had any cancer besides non-melanoma skin cancer in the last 5 years.My liver tests are within normal limits.I have a new diagnosis of a serious bladder cancer and am eligible for major surgery or radiation.More than half of my cancer cells are not urothelial carcinoma.I need considerable assistance and cannot care for myself.I've had pelvic surgery that affects lymph node removal.I am being considered for a treatment aimed at curing my condition.I cannot lie on my back for a PET-CT scan.I am under 18 years old.
Research Study Groups:
This trial has the following groups:- Group 1: No PET-CT
- Group 2: Whole-body FDG PET-CT
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are participants being enrolled in this research project currently?
"Data posted on clinicaltrials.gov indicates that this study is not currently recruiting patients, although it was initially established in May of 2016 and last updated in April 2022. Unfortunately, there are no open spots at present; however, other trials have 432 available locations for potential participants."
Answered by AI
How many facilities are currently carrying out this research?
"This clinical trial is being conducted across 6 different medical facilities, including Princess Margaret Cancer Centre in Toronto, Juravinski Cancer Centre in Hamilton, and London Regional Cancer Centre in London. Additionally, three other locations are participating."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger